Drug Trial Radar · NCT07239986
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 2025
Primary completion
Jun 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Broadenbio Ltd., Co.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
BB102Drug
Oral BB102 Tablets in two dosage
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: From enrollment to the end of treatment assessed up to 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.